Related Experiment Video
Updated: Aug 11, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
[Flowcytometric-immunophenotyping for leukemia needs to be standardized]
1Institute of Hematology, The People's Hospital, Peking University, Beijing 100044, China. chenss@public.bta.net.cn
Insights
Flowcytometric immunophenotyping (FCM-IM) aids in diagnosing hematological malignancies like leukemias and lymphoid proliferative disorders. Accurate interpretation requires multi-color analysis, CD45/SSC gating for pure cell populations, and cautious diagnosis of hybrid leukemia.
Area of Science:
- Hematology
- Immunology
- Clinical Pathology
Context:
- Flow cytometry is widely used in hospitals for routine tests.
- Immunophenotyping by flow cytometry is crucial for diagnosing hematological malignancies.
- Accurate diagnosis of leukemias and lymphoid proliferative disorders (LPDs) relies on FCM-IM.
Purpose:
- To highlight the indispensable role of flowcytometric immunophenotyping (FCM-IM) in diagnosing hematological malignancies.
- To outline critical parameters for accurate FCM-IM interpretation and standardization.
- To emphasize the need for multi-parameter analysis and proper cell population gating.
Summary:
- FCM-IM facilitates accurate diagnosis of leukemias and LPDs, providing therapeutically relevant information.
- Key diagnostic considerations include direct multi-color staining, CD45/SSC gating for blast population isolation, and clear phenotype description.
- Caution is advised for hybrid leukemia diagnoses based solely on FCM, considering antigen variability and lineage infidelity.
Impact:
- Standardized FCM-IM protocols improve diagnostic accuracy and inter-laboratory consistency.
- Proper application of FCM-IM enhances the diagnosis and management of hematological cancers.
- This technique provides critical data for clinical decision-making in hematologic oncology.
Abstract:
Flowcytometer has been flourishing since the passed decade in our nation. Many general hospitals use it for routine tests. One of the main usage is immunophenotyping for hematological malignancies. Flowcytometric immunophenotyping (FCM-IM) facilitates accurate diagnosis in both leukemias and lymphoid proliferative disorders (LPDs). It becomes an indispensable criteria in the diagnosis of hematological malignancies. It may also offer additional therapeutically relevant information. Typical patterns of immunophenotype in leukemias and certain types of LPDs are illustrated in figure 1 and figure 2. But variation or overlapping appears often. In order to reach a definitive diagnosis and to have a common interpretation between laboratory to laboratory the following items need not to be ignored: 1. Direct staining and multi-color or multi-parameter flow cytometric analysis is necessary. 2. The phenotype of abnormal cells should be determined on as pure a population as possible therefore CD45/SSC gating is critical for isolating the blast population (abnormal cells). CD45/SSC gating is much better than FSC/SSC gating especially when percentage of blast is low in the sample. Else, each subtype of leukemia has its special CD45/SSC pattern. 3. The phenotype of this certain population should be described clearly but it is not necessary to count the percentage of each marker. 4. > 20% for positive threshold used in indirect staining method may be confused in multi-color direct staining method. 5. Hybrid leukemia diagnosed by FCM only should be in caution since the divergence of antigen/antibody, the lineage infidelity of antigen expression and the biological characteristics of the leukemic cells. Flowcytometer is not a cell counter. "It provides a pattern of information that must be interpreted by a knowledgeable professional in the context of the clinical situation".
More Related Videos
05:24Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
Published on: February 21, 2021
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025